Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Sex Differences in Resting Metabolic Rate among Athletes and Association with Body Composition Parameters: A Follow-Up Investigation
Jagim, Andrew R. , Jones, Margaret T. , Askow, Andrew T. , Luedke, Joel, Erickson, Jacob L. , Fields, Jennifer B. , Kerksick, Chad M. , Jagim, Andrew R , Kerksick, Chad M , Askow, Andrew T

Mayo Clinic

Journal of Functional Morphology and Kinesiology | August 3, 2023 | Volume: 8 | Issue: 3 | Pages: 109

10.3390/jfmk8030109 | PMID 37606404 Get It

The purpose of this study was to examine sex differences in resting metabolic rate (RMR) and associations between measured RMR and body composition parameters in athletes. One-hundred and ninety collegiate men (n = 98; age: 20.1 ± 1.6 yr.; body mass: 92.7 ± 17.5 kg; height: 181.6 ± 6.2 cm, body mass index: 28.0 ± 4.7 kg/m2) and women (n = 92; age: 19.4 ± 1.1 yr.; body mass: 65.2 ± 11.0 kg; height: 168.0 ± 6.6 cm, body mass index: 23.0 ± 3.6 kg/m2) athletes volunteered to participate in this study. Athletes completed a body composition assessment using air displacement plethysmography and RMR using indirect calorimetry. Assessments were completed in a fasted state and after refraining from intense physical activity > 24 h prior to testing. Data were collected during the 2016–2019 seasons. Men had a higher RMR compared to women (2595 ± 433 vs. 1709 ± 308 kcals; p < 0.001); however, when adjusted for body mass (p = 0.064) and fat-free mass (p = 0.084), the observed differences were not significant. Height, body mass, body mass index, fat-free mass, and fat mass were positively associated with RMR in both men and women athletes (r = 0.4–0.8; p < 0.001). Body mass (men: β = 0.784; women: β = 0.832)) was the strongest predictor of RMR. Men athletes have a higher absolute RMR compared to their women counterparts, which is influenced by greater body mass and fat-free mass. Body mass is the strongest predictor of RMR in both men and women athletes.
Neurofilament Light Chain in Spinal Fluid and Plasma in Multiple System Atrophy – A Prospective, Longitudinal Biomarker Study
Singer, Wolfgang , Schmeichel, Ann M., Sletten, David M., Gehrking, Tonette L., Gehrking, Jade A., Trejo‐Lopez, Jorge , Suarez, Mariana, Anderson, Jennifer K., Bass, Pamela H., Lesnick, Timothy G. , Low, Phillip A. , Suarez, Mariana D., Singer, Wolfgang , Anderson, Jennifer K.

Mayo Clinic

No container title available | August 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3201386/v1 | PMID 37577499 Get It

Abstract Purpose There is a critical need for reliable diagnostic biomarkers as well as surrogate markers of disease progression in multiple system atrophy (MSA). Neurofilament light chain (NfL) has been reported to potentially meet those needs. We therefore sought to explore the value of NfL in plasma (NfL-p) in contrast to CSF (NfL-c) as diagnostic marker of MSA, and to assess NfL-p and NfL-c as markers of clinical disease progression. Methods Well-characterized patients with early MSA (n=32), Parkinson’s disease (PD, n=21), and matched controls (CON, n=15) were enrolled in a prospective, longitudinal study of synucleinopathies with serial annual evaluations. NfL was measured using a high sensitivity immunoassay, and findings were assessed by disease category and relationship with clinical measures of disease progression. Results Measurements of NfL-c were highly reproducible across immunoassay platforms (Pearson,r=0.99), while correlation between NfL-c and -p was only moderate (r=0.66). NfL was significantly higher in MSA compared to CON and PD; the separation was essentially perfect for NfL-c, but there was overlap, particularly with PD, for NfL-p. While clinical measures of disease severity progressively increased over time, NfL-c and -p remained at stable elevated levels within subjects across serial measurements. Neither change in NfL nor baseline NfL were significantly associated with changes in clinical markers of disease severity. Conclusions These findings confirm NfL-c as faithful diagnostic marker of MSA, while NfL-p showed less robust diagnostic value. The significant NfL elevation in MSA was found to be remarkably stable over time and was not predictive of clinical disease progression.
Pediatric Knee Arthroscopy: The Basics of Pediatric Knee Arthroscopy from a Collection of Pediatric Sports Medicine Experts
Kirby, Julia, Johnson, B. Lamar , Millewski, Matt, Shea, Kevin G. , Beck, Jennifer J. , Milbrandt, Todd A. , Pace, Lee, Vandenberg, Curt, Tompkins, Marc , Gamble, James G. , Ganley, Ted, Ellis, Henry B. , Milbrandt, Todd, Ellis, Henry B , Millewski, Matthew, Wilson, Philip L. , Schmitz, Matthew R. , Edmonds, Eric W. , Yen, Yi‐Meng

Mayo Clinic

Video Journal of Sports Medicine | August 1, 2023 | Volume: 3 | Issue: 4 | Pages: No page available

10.1177/26350254231168160 | PMID 40308682 Get It

Background/Objective: To share technical pearls of a basic knee arthroscopy in a pediatric patient by presenting tips and tricks used by experienced pediatric arthroscopists. Indications: Knee arthroscopy is a common procedure performed by most orthopedic surgeons. However, technical considerations and equipment should be considered before performing this procedure in a pediatric patient. This video provides information on indications, equipment, and patient positioning, as well as outlining a systematic approach to diagnostic arthroscopy and pertinent pediatric anatomy. Discussion/Conclusion: This video provides an excellent overview as well as specific pathology-dependent considerations for the inexperienced orthopedic surgeon, or the orthopedic surgeon who rarely performs knee arthroscopy. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss, Aaron R. , Scharschmidt, Thomas J. , Xue, Wei , Gao, Zhengya, Black, Jennifer O. , Choy, Edwin , Fanburg–Smith, Julie C. , Kao, Simon C. , Kayton, Mark L. , Kessel, Sandy, Lim, Ruth , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Parisi, Marguerite T. , Pryma, Daniel A. , Rosen, Mark, Terezakis, Stephanie , Venkatramani, Rajkumar , Zambrano, Eduardo , Wang, Dian , Hawkins, Douglas S. , Black, Jennifer O , Choy, Edwin , Kao, Simon C , Kayton, Mark L , Lim, Ruth , Million, Lynn , Okuno, Scott , Ostrenga, Andrew , Pryma, Daniel A , Randall, Robert Lor , Shulkin, Barry L , Terezakis, Stephanie A , Venkatramani, Rajkumar , Wang, Dian , Hawkins, Douglas S , Spunt, Sheri L , Weiss, Aaron R , Chen, Yen‐Lin , Davis, Jessica L. , Randall, R. Lor , Shulkin, Barry L. , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | July 31, 2023 | Volume: 41 | Issue: 31 | Pages: 4842-4848

10.1200/jco.23.00045 | PMID 37523624 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.
Evaluation of Novel Targets, Including CC-Chemokine Receptor 4, in Adult T-Cell Acute Lymphoblastic Leukemia/Lymphoma: A Mayo Clinic Clinical and Pathologic Study
Khurana, Sharad , Craig, Fiona E. , Cochuyt, Jordan J., Rahman, Zaid Abdel , Sproat, Lisa Z., Litzow, Mark R. , Foran, James M. , Jiang, Liuyan , Rahman, Zaid H. Abdel , Greipp, Patricia, Jiang, Liuyan Jennifer, Abdel Rahman, Zaid H , Heckman, Michael G. , Greipp, Patricia T.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 31, 2023 | Volume: 148 | Issue: 4 | Pages: 471-475

10.5858/arpa.2022-0482-oa | PMID 37522711 Get It

Context.— Unlike B-cell acute lymphoblastic leukemia/lymphoma (ALL/LBL), there have been few therapeutic advances in T-cell ALL (T-ALL)/LBL, an aggressive ALL/LBL subtype. Objective.— To perform a focused tissue array study to elucidate tumor markers of therapeutic potential in T-ALL/LBL. Design.— Using immunohistochemistry, we evaluated expression of leukemic antigens of interest, specifically CC-chemokine receptor 4 (CCR4), among others, on available remnant diagnostic material, including tumor tissue slides obtained from formalin-fixed, paraffin-embedded preserved tissues. Results.— Our analysis identified, for the first time, expression of CCR4 in T-ALL/LBL in 11 of 27 cases (40.7%) and confirmed common expression of BCL2, CD38, and CD47, as reported previously. We also identified the expression of CD123 in 4 of 26 cases (15.4%), whereas BCL6 and PDL1 were expressed in a small number of T-ALL/LBL cases. The potential novel target CCR4 was significantly more common in the Pre/Pro-T immunophenotypic subtype, 6 of 9 (66.7%, P = .01). No additional differences in clinical and epidemiologic variables were noted among positive or negative CCR4 cases. Conclusions.— These findings support preclinical and clinical testing of therapies targeting CCR4, CD47, BCL2, CD38, and CD123 in T-ALL/LBL, and may help guide the development of targeted clinical trials in T-ALL/LBL, a rare disease in urgent need of novel therapies.
Machine Learning-Based Prediction of in-Hospital Death for Patients with Takotsubo Syndrome: The InterTAK-ML Model
Filippo, Ovidio De , Cammann, Victoria L. , Vece, Davide Di , Schweiger, Victor , Niederseer, David , Szawan, Konrad A. , Würdinger, Michael , Koleva, Iva, Bellino, Michele , Vecchione, Carmine , Bossone, Eduardo , Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Jansen, Thomas , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Cuculi, Florim , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Akın, İbrahim , Poledníková, Karolína, Winchester, David E. , Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio, Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Liu, Kan , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Bruno, Francesco , Kong, William , Dalakoti, Mayank , Imori, Yoichi , Münzel, Thomas , Crea, Filippo , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Bossone, Eduardo , Vecchione, Carmine , Bruno, Francesco , von Lewinski, Dirk , Tschöpe, Carsten , Meyer, Philippe , Bilato, Claudio , Pancotti, Corrado , Silverio, Angelo , Dusi, Veronica , Parodi, Guido , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Himi, Toshiharu, Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T. , Ferrari, Gaetano Maria De , Fariselli, Piero , Citro, Rodolfo , D’Ascenzo, Fabrizio

Mayo Clinic

European Journal of Heart Failure | July 31, 2023 | Volume: 25 | Issue: 12 | Pages: 2299-2311

10.1002/ejhf.2983 | PMID 37522520 Get It

ABSTRACT Aims Takotsubo syndrome (TTS) is associated with a substantial rate of adverse events. We sought to design a machine learning (ML)-based model to predict the risk of in-hospital death and to perform a clustering of TTS patients to identify different risk profiles. Methods and results A ridge logistic regression-based ML model for predicting in-hospital death was developed on 3482 TTS patients from the International Takotsubo (InterTAK) Registry, randomly split in a train and an internal validation cohort (75% and 25% of the sample size, respectively) and evaluated in an external validation cohort (1037 patients). Thirty-one clinically relevant variables were included in the prediction model. Model performance represented the primary endpoint and was assessed according to area under the curve (AUC), sensitivity and specificity. As secondary endpoint, a K-medoids clustering algorithm was designed to stratify patients into phenotypic groups based on the 10 most relevant features emerging from the main model. The overall incidence of in-hospital death was 5.2%. The InterTAK-ML model showed an AUC of 0.89 (0.85–0.92), a sensitivity of 0.85 (0.78–0.95) and a specificity of 0.76 (0.74–0.79) in the internal validation cohort and an AUC of 0.82 (0.73–0.91), a sensitivity of 0.74 (0.61–0.87) and a specificity of 0.79 (0.77–0.81) in the external cohort for in-hospital death prediction. By exploiting the 10 variables showing the highest feature importance, TTS patients were clustered into six groups associated with different risks of in-hospital death (28.8% vs. 15.5% vs. 5.4% vs. 1.0.8% vs. 0.5%) which were consistent also in the external cohort. Conclusion A ML-based approach for the identification of TTS patients at risk of adverse short-term prognosis is feasible and effective. The InterTAK-ML model showed unprecedented discriminative capability for the prediction of in-hospital death.
Treatment‐responsive glycogen storage myopathy in a patient with POEMS syndrome: A new monoclonal gammopathy‐associated myopathy
Soontrapa, Pannathat , Tracy, Jennifer A., Liewluck, T , Soontrapa, Pannathat , Gonsalves, Wilson I. , Liewluck, Teerin

Mayo Clinic

European Journal of Neurology | July 31, 2023 | Volume: 30 | Issue: 10 | Pages: 3404-3406

10.1111/ene.16008 | PMID 37522432 Get It

Abstract Background Myopathies associated with monoclonal gammopathy are relatively uncommon and underrecognized, treatable myopathies, and include sporadic late onset nemaline myopathy, light chain amyloid myopathy, and a recently described vacuolar myopathy with monoclonal gammopathy and stiffness (VAMGS). Herein, we report a new subtype of monoclonal gammopathy‐associated myopathy (MGAM) in a polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) patient. Method Case report. Results A 51‐year‐old woman presented with a 6‐month history of progressive bilateral foot drop, lower limb edema, and a 15‐lb weight loss. She denied muscle stiffness. Neurologic exam showed severe distal weakness, mild proximal weakness, and length‐dependent sensory deficits. Laboratory studies revealed biclonal gammopathy (IgG kappa and IgA lambda), thrombocytosis, and elevated vascular endothelial growth factor. Creatine kinase was normal. Electrodiagnostic studies identified mixed demyelinating and axonal polyradiculoneuropathy and a superimposed proximal myopathy. Gluteus medius biopsy demonstrated scattered fibers with glycogen‐filled vacuoles, similar to VAMGS, with additional rare myofibers containing polyglucosan bodies. She was diagnosed with POEMS syndrome and concomitant glycogen storage myopathy. Next‐generation sequencing of glycogen storage and polyglucosan body myopathy‐related genes was unrevealing. Proximal weakness resolved after autologous stem cell transplant. Conclusions This patient expands a spectrum of MGAM. Recognition of this condition and other subtypes of MGAM is of utmost important because they are treatable.
Prophylactic effect of chronic immunosuppression in a mouse model of CSF‐1 receptor‐related leukoencephalopathy
Oppong‐Asare, Jude, Gökhan, Şölen, Aguilan, Jennifer T. , Dulski, Jarosław , Wszolek, Z., Stanley, E. Richard , Dulski, Jaroslaw , Wszolek, Zbignew K, Stanley, E Richard , Chiţu, Violeta , Biundo, Fabrizio , Sidoli, Simone

Mayo Clinic

Glia | July 31, 2023 | Volume: 71 | Issue: 11 | Pages: 2664-2678

10.1002/glia.24446 | PMID 37519044 Get It

AbstractMutations leading to colony‐stimulating factor‐1 receptor (CSF‐1R) loss‐of‐function or haploinsufficiency cause CSF1R‐related leukoencephalopathy (CRL), an adult‐onset disease characterized by loss of myelin and neurodegeneration, for which there is no effective therapy. Symptom onset usually occurs in the fourth decade of life and the penetrance of disease in carriers is high. However, familial studies have identified a few carriers of pathogenic CSF1R mutations that remain asymptomatic even in their seventh decade of life, raising the possibility that the development and severity of disease might be influenced by environmental factors. Here we report new cases in which long‐term glucocorticoid treatment is associated with asymptomatic status in elder carriers of pathogenic CSF‐1R mutations. The main objective of the present study was to investigate the link between chronic immunosuppression initiated pre‐symptomatically and resistance to the development of symptomatic CRL, in the Csf1r+/− mouse model. We show that chronic prednisone administration prevents the development of memory, motor coordination and social interaction deficits, as well as the demyelination, neurodegeneration and microgliosis associated with these deficits. These findings are in agreement with the preliminary clinical observations and support the concept that pre‐symptomatic immunosuppression is protective in patients carrying pathogenic CSF1R variants associated with CRL. Proteomic analysis of microglia and oligodendrocytes indicates that prednisone suppresses processes involved in microglial activation and alleviates senescence and improves fitness of oligodendrocytes. This analysis also identifies new potential targets for therapeutic intervention.
Preemptive Venoarterial Extracorporeal Membrane Oxygenation for Liver Transplantation—Judicious Candidate Selection
Lee, Jennifer , Allen, Wesley L. , Scott, Courtney L. , Aniskevich, Stephen , Aniskevich, Stephen , Pai, Sher‐Lu

Mayo Clinic

Journal of Clinical Medicine | July 28, 2023 | Volume: 12 | Issue: 15 | Pages: 4965

10.3390/jcm12154965 | PMID 37568367 Get It

Portopulmonary hypertension is a relatively common pathologic condition in patients with end-stage liver disease. Traditionally, severe pulmonary hypertension is regarded as a contraindication to liver transplantation (LT) due to a high perioperative mortality rate. Recently, extracorporeal membrane oxygenation (ECMO) has been utilized for intraoperative management of LT. As venoarterial (VA) ECMO may benefit certain high-risk LT patients by reducing the ventricular workload by the equivalent of the programmed flow rate, its usage requires multidisciplinary planning with considerations of the associated complications. We highlighted two cases at our single-center institution as examples of high-risk pulmonary hypertension patients undergoing LT on planned VA ECMO. These patients both survived the intraoperative period; however, they had drastically different postoperative outcomes, generating discussions on the importance of judicious patient selection. Since ECMO has removed the barrier of intraoperative survivability, the patient selection process may need to put weight on the patient’s potential for postoperative recovery and rehabilitation. Considerations on LT recipients undergoing preemptive ECMO need to expand from the ability of the patients to withstand the demands of the surgery during the immediate perioperative period to the long-term postoperative recovery course.
Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme
Lickliter, Jason D. , Ruben, Jeremy , Kichenadasse, Ganessan , Jennens, Ross , Gzell, Cecelia , Mason, Ralph P. , Zhou, Heling , Becker, Jennifer , Unger, Evan C. , Stea, Baldassarre , Unger, Evan

Mayo Clinic

Cancer Research Communications | July 26, 2023 | Volume: 3 | Issue: 8 | Pages: 1607-1614

10.1158/2767-9764.crc-22-0433 | PMID 37609003 Get It

Purpose: Glioblastoma multiforme (GBM) is a hypoxic tumor resistant to radiotherapy. The purpose of this study was to assess the safety and efficacy of a novel oxygen therapeutic, dodecafluoropentane emulsion (DDFPe), in chemoradiation treatment of GBM. Experimental Design: In this multicenter phase Ib/II dose-escalation study, patients were administered DDFPe via intravenous infusion (0.05, 0.10, or 0.17 mL/kg) while breathing supplemental oxygen prior to each 2 Gy fraction of radiotherapy (30 fractions over 6 weeks). Patients also received standard-of-care chemotherapy [temozolomide (TMZ)]. Serial MRI scans were taken to monitor disease response. Adverse events were recorded and graded. TOLD (tissue oxygenation level–dependent) contrast MRI was obtained to validate modulation of tumor hypoxia. Results: Eleven patients were enrolled. DDFPe combined with radiotherapy and TMZ was well tolerated in most patients. Two patients developed delayed grade 3 radiation necrosis during dose escalation, one each at 0.1 and 0.17 mL/kg of DDFPe. Subsequent patients were treated at the 0.1 mL/kg dose level. Kaplan–Meier analysis showed a median overall survival of 19.4 months and a median progression-free survival of 9.6 months, which compares favorably to historical controls. Among 6 patients evaluable for TOLD MRI, a statistically significant reduction in tumor T1 was observed after DDFPe treatment. Conclusions: This trial, although small, showed that the use of DDFPe as a radiosensitizer in patients with GBM was generally safe and may provide a survival benefit. This is also the first time than TOLD MRI has shown reversal of tumor hypoxia in a clinical trial in patients. The recommended dose for phase II evaluation is 0.1 mL/kg DDFPe. Trial Registration: NCT02189109 Significance: This study shows that DDFPe can be safely administered to patients, and it is the first-in-human study to show reversal of hypoxia in GBM as measured by TOLD MRI. This strategy is being used in a larger phase II/III trial which will hopefully show a survival benefit by adding DDFPe during the course of fractionated radiation and concurrent chemotherapy.